iPS-NR2E3-86

General

Cell Line

hPSCreg name IDVi001-A
Cite as:
IDVi001-A (RRID:CVCL_QX82)
Alternative name(s)
iPS-NR2E3-86
Cell line type Human induced pluripotent stem cell (hiPSC)
Similar lines
WTSIi691-A
(HPSI1116i-eiyy_1)
Donor diseases:
Retinitis pigmentosa
WTSIi693-A
(HPSI1116i-zies_2)
Donor diseases:
Retinitis pigmentosa
WTSIi698-A
(HPSI1116i-aimh_5)
Donor diseases:
Retinitis pigmentosa
WTSIi713-A
(HPSI0816i-xoga_7)
Donor diseases:
Retinitis pigmentosa
WTSIi693-B
(HPSI1116i-zies_6)
Donor diseases:
Retinitis pigmentosa
WTSIi698-B
(HPSI1116i-aimh_3)
Donor diseases:
Retinitis pigmentosa
WTSIi688-B
(HPSI1116i-wiau_4)
Donor diseases:
Retinitis pigmentosa
WTSIi613-B
(HPSI1116i-rafd_1)
Donor diseases:
Retinitis pigmentosa
WTSIi613-A
(HPSI1116i-rafd_4)
Donor diseases:
Retinitis pigmentosa
LUMCi056-A-1
(LUMC0128iCRB01 heterozygote CRISPR corrected isogenic clone 02, iso02LUMC0128iCRB01)
Donor's gene variants:
CRB1, CRB1
Donor diseases:
Retinitis Pigmentosa
WTSIi713-B
(HPSI0816i-xoga_12)
Donor diseases:
Retinitis pigmentosa
WTSIi688-A
(HPSI1116i-wiau_1)
Donor diseases:
Retinitis pigmentosa
WTSIi694-A
(HPSI0816i-oemk_6)
Donor diseases:
Retinitis pigmentosa
WTSIi463-A
(HPSI0716i-yibs_1)
Donor diseases:
Retinitis pigmentosa
RIi012-A
(RP.1.H.iPSC.2)
Donor diseases:
Retinitis pigmentosa
WTSIi659-B
(HPSI1116i-wakr_6)
Donor diseases:
Retinitis pigmentosa
WTSIi610-A
(HPSI1116i-naum_5)
Donor diseases:
Retinitis pigmentosa
WTSIi659-A
(HPSI1116i-wakr_3)
Donor diseases:
Retinitis pigmentosa
WTSIi463-B
(HPSI0716i-yibs_3)
Donor diseases:
Retinitis pigmentosa
UNEWi001-A
(UNEW001Ai)
Donor's gene variants:
PRPF31
Donor diseases:
Retinitis pigmentosa
UNEWi002-A
(UNEW002Ai, PRPF31 AW)
Donor's gene variants:
PRPF31, PRPF31
Donor diseases:
Retinitis pigmentosa
UNEWi003-A
(PRPF31-HD)
Donor diseases:
Retinitis pigmentosa
ESi077-A
(CABi001-A, PRPF31-MiPS4F3)
Donor's gene variants:
PRPF31, PRPF31
Donor diseases:
Retinitis Pigmentosa
CIRMi525-A
(CW70348)
Donor diseases:
retinitis pigmentosa
FRIMOi002-A
(RP2_FiPS4F2.2)
Donor diseases:
Retinitis Pigmentosa
FRIMOi005-A
(RP3_FiPS4F11)
Donor diseases:
Retinitis Pigmentosa
UNEWi027-A
(F116)
Donor's gene variants:
PRPF31
Donor diseases:
Retinitis pigmentosa
UNEWi004-A
(PRPF31 SH)
Donor's gene variants:
PRPF31
Donor diseases:
Retinitis pigmentosa
UNEWi005-A
(PRPF31 RH)
Donor's gene variants:
PRPF31
Donor diseases:
Retinitis pigmentosa
CIRMi508-A
(CW70323)
Donor diseases:
retinitis pigmentosa
CIRMi519-A
(CW70342)
Donor diseases:
retinitis pigmentosa
MUi038-A
(EYS mutation)
Donor diseases:
retinitis pigmentosa
FRIMOi001-A
(RP1_FiPS4F1.6)
Donor diseases:
Retinitis Pigmentosa
LUMCi055-A
(CRB1 patient 117 compound heterozygous 2983G>T p.(Glu995*) c.1892A>G, p.(Tyr631Cys), LUMC0117iCRB01)
Donor's gene variants:
CRB1, CRB1
Donor diseases:
Retinitis Pigmentosa
CIRMi531-A
(CW70356)
Donor diseases:
retinitis pigmentosa
LUMCi056-A
(CRB1 patient 128 compound heterozygous c.2843G>A p.(Cys948Tyr) and c.3122T>C p.(Met1041Thr), LUMC0128iCRB01)
Donor's gene variants:
CRB1, CRB1
Donor diseases:
Retinitis Pigmentosa
CABi002-A
(OF0176-EYS02-C7, EYS02-MiPS4F7)
Donor diseases:
Retinitis Pigmentosa
CIRMi542-A
(CW70373)
Donor diseases:
retinitis pigmentosa
NUIGi027-A
(RP001C8)
Donor diseases:
Retinitis Pigmentosa
NUIGi028-A
(RP002C12)
Donor diseases:
Retinitis Pigmentosa
NUIGi029-A
(RP003C12)
Donor diseases:
Retinitis Pigmentosa
RIi009-A
(RP2.H.iPSC.3)
Donor diseases:
Retinitis pigmentosa
Last update 6th June 2019
User feedback
No feedback available yet.

Login to share your feedback, experiences or results with the research community.

Provider

Generator INSTITUT DE LA VISION (IDV)
Owner INSTITUT DE LA VISION (IDV)
Distributors
Derivation country France

External Databases

Cellosaurus CVCL_QX82
BioSamples SAMEA994012
Wikidata Q54897303

General Information

Publications
Projects
* Is the cell line readily obtainable for third parties?
No

Donor Information

General Donor Information

Sex female
Age of donor (at collection) 45-49
Ethnicity caucasian

Phenotype and Disease related information (Donor)

Diseases A disease was diagnosed.
The donor is a carrier of a disease-associated mutation and affected.
Disease associated phenotypes
  • blindness
Family history -
Is the medical history available upon request? no
Is clinical information available? no

Karyotyping (Donor)

Has the donor karyotype been analysed?
Yes
see paper: Terray et al. Stem Cell Research 2017, 24:1-4
Karyotyping method: Molecular karyotyping by SNP array

Other Genotyping (Donor)

Is there genome-wide genotyping or functional data available?
No

External Databases (Donor)

BioSamples SAMEA654195

Ethics

Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? Yes
Was the consent voluntarily given? Yes
Has the donor been informed that participation will not directly influence their personal treatment? Yes
Can you provide us with a copy of the Donor Information Sheet provided to the donor? Yes
Do you (Depositor/Provider) hold the original Donor Consent Form? No
If you do not hold the Donor Consent Form, do you know who does? Yes
Please provide the contact information Dr Isabelle AUDO (isabelle.audo@inserm.fr)
Alternatives to consent are available? No
Is there other documentation provided to the donor for consenting purposes? No
Confirm that consent was obtained by a qualified professional Yes
Has the donor agreed to be re-contacted? Unknown
Has the donor been informed about how her/his data will be protected? Yes
Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. anonymised
Does consent explicitly allow the derivation of pluripotent stem cells? No
Does consent expressly prevent the derivation of pluripotent stem cells? Yes
Does consent pertain to a specific research project? Yes
Details on restriction to research project Generation of iPS cells from patients affecting by Retinitis Pigmentosa
Does consent permit unforeseen future research, without further consent? Yes
Does the consent permit uses of donated embryo/tissue or derived cell line intended for clinical treatment or human applications? No
Does consent expressly prevent development of commercial products? Yes
Does consent expressly prevent financial gain from any use of the donated embryo/tissue, including any product made from it? Yes
Does consent expressly permit storage of donated embryo/tissue for an unlimited time? Yes
Does consent expressly permit storage of cells derived from the donated embryo/tissue for an unlimited time? Yes
Does consent prevent the DONATED BIOSAMPLE from being made available to researchers anywhere in the world? No
Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? No

Does consent permit research by

an academic institution? Yes
a public organisation? No
a non-profit company? No
a for-profit corporation? No
Does consent expressly permit collection of genetic information? No
Does consent expressly permit storage of genetic information? No
Does consent prevent dissemination of genetic information? No
Has the donor been informed that their donated biosample or derived cells may be tested for the presence of microbiological agents / pathogens? No
Has the donor consented to receive information discovered during use of donated embryo/tissue that has significant health implications for the donor? No
How may genetic information associated with the cell line be accessed? No information
Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? No
Does the consent anticipate that the donor will be notified of results or outcomes of any research involving the donated samples or derived cells? Yes
Does the consent permit the donor, upon withdrawal of consent, to stop the use of the derived cell line(s) that have already been created from donated samples? Yes
Does the consent permit the donor, upon withdrawal of consent, to stop delivery or use of information and data about the donor? Yes
Does consent permit access to medical records of the donor? No
Does consent permit access to any other source of information about the clinical treatment or health of the donor? No
Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? Yes
Name of accrediting authority involved? CPP Ile de France and the ANSM
Approval number 2012-A01333–40; P12-02 and B121362-32
Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the PROPOSED PROJECT, involving use of donated embryo/tissue or derived cells? Yes
Name of accrediting authority involved? CPP Ile de France and the ANSM
Approval number 2012-A01333–40; P12-02 and B121362-32
Do you have obligations to third parties in regard to the use of the cell line? No
Are you aware of any further constraints on the use of the donated embryo/tissue or derived cells? No
Is there an MTA available for the cell line? No
For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used?
Are you aware of any constraints on the use or distribution of the cell line from the owner or any parties identified in the query above? No

hIPSC Derivation

General

Source cell type
A connective tissue cell which secretes an extracellular matrix rich in collagen and other macromolecules. Flattened and irregular in outline with branching processes; appear fusiform or spindle-shaped.; These cells may be vimentin-positive, fibronectin-positive, fsp1-positive, MMP-1-positive, collagen I-positive, collagen III-positive, and alpha-SMA-negative.
Source cell origin
Any portion of the organ that covers that body and consists of a layer of epidermis and a layer of dermis.
Synonyms
  • portion of skin
  • region of skin
  • skin
  • skin region
  • skin zone
show more synonyms
Age of donor (at collection) 45-49
Passage number reprogrammed 1

Reprogramming method

Vector type Non-integrating
Vector Sendai virus
Is reprogramming vector detectable?
No
Methods used
RT-PCR

Vector free reprogramming

Type of used vector free reprogramming factor(s)
None

Other

Selection criteria for clones morphology
Derived under xeno-free conditions
No
Derived under GMP?
No
Available as clinical grade?
No

Culture Conditions

Surface coating Vitronectin
Feeder cells
No
Passage method Enzyme-free cell dissociation
Gentle Cell Dissociation Reagent
O2 Concentration 20 %
CO2 Concentration 5 %
Medium mTeSR™ 1
Has Rock inhibitor (Y27632) been used at passage previously with this cell line?
No
Has Rock inhibitor (Y27632) been used at cryo previously with this cell line?
No
Has Rock inhibitor (Y27632) been used at thaw previously with this cell line?
No

Characterisation

Analysis of Undifferentiated Cells
Marker Expressed Immunostaining RT-PCR Flow Cytometry Enzymatic Assay Expression Profiles
NANOG
Yes
POU5F1 (OCT-4)
Yes
SSEA-4
Yes
TRA 1-60
Yes
TRA 1-81
Yes
Alkaline Phosphatase
Yes
See paper: Terray et al. Stem Cell Research 2017, 24:1-4
Transcriptome Characterisation
Differentiation Potency
Endoderm
Ont Id: UBERON_0000925
In vivo teratoma
Mesoderm
Ont Id: UBERON_0000926
In vivo teratoma
Ectoderm
Ont Id: UBERON_0000924
In vivo teratoma

Microbiology / Virus Screening

Mycoplasma Negative

Genotyping

Karyotyping (Cell Line)

Has the cell line karyotype been analysed?
Yes
see paper: Terray et al. Stem Cell Research 2017, 24:1-4
Passage number: 31
Karyotyping method: Molecular karyotyping by SNP array

Other Genotyping (Cell Line)